Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Investment

Low return world a boon for VC

A number of institutional investors are proving the health sciences venture capital space holds significant potential for Australian investors, with funding from the likes of QIC and Hostplus driving major pharmaceutical developments.

Upgrade your subscription to access this article

And gain access to:
  • All website content, including archived news
  • Home page news customisation
  • Tech Zone, your technical resource library
And more
Already A Subscriber?

Read more: QIC,  Hostplus,  Hatchtech,  VC,  Marcus Simpson,  Brandon Capital Partners,  Commonwealth of Australia,  Aravax,  Australian Private Equity,  Australian Super,  HESTA,  Information Technology,  Innovation Foundation,  Nexvet,  Novartis International for,  Sam Sicilia,  Spinifex Pharmaceuticals,  Statewide Super,  Sydney,  United States,  Venture Capital Association